BioLife Solutions competitors

Key experiences in leading mergers and acquisitions, working with financial institutions and markets, driving exceptional growth in revenue and profit, developing organizations, managing organizational performance, and planning strategic growth. Specialties: Mergers and acquisitions, General Management, Marketing, Sales, Quality Systems.

Terry Rich works at NUVASIVE INC and a President/CEO at RTI SURGICAL, INC. and Board Member at RTI SURGICAL, INC.. He has worked as Board Member at ALPHATEC HOLDINGS, INC.; Senior VP:Sales at NUVASIVE INC; and President/COO at ALPHATEC HOLDINGS, INC.. Terry attended Rutgers University.

Mr. Dominick C. Colangelo joined Promedior in December 2008 with fifteen years of pharmaceutical industry experience, including nearly a decade with Eli Lilly and Company. During his career, Mr. Colangelo has held a variety of executive positions of increasing responsibility in finance, product development, pharmaceutical operations, and corporate business development. During his tenure at Eli Lilly and Company, Mr. Colangelo held positions as an international tax attorney in the finance organization and as Director of Strategy and Business Development for Lilly’s Diabetes and Growth Disorders Product Group. He also served as a founding Managing Director of Lilly Ventures. Mr. Colangelo received a B.S.B.A. degree in Accounting from the State University of New York at Buffalo and a J.D. degree from the Duke University School of Law.

Dynamic, results-oriented leader with a strong track record of performance in turnaround and high-paced organizations. Utilize keen analysis and insights and team approach to drive organizational improvements and implementation of best practices. Superior interpersonal skills, capable of resolving multiple and complex (sales, human resources, legal, financial, operational) issues and motivating staff to peak performance. Excellent political connections developed as selected member of Fiorello LaGuardia's mayoral team.

John Ducker is a Plant Manager at Fresenius SE Group, President/CEO at Fresenius Kabi USA, and Director at FRANCESCA'S HOLDINGS CORP. He has worked as Board Member at FRESENIUS KABI ONCOLOGY LIMITED, President/CEO at App Pharmaceuticals Inc., and Board Member at Dabur Pharma Co. Ltd. John studied at University of Cambridge.

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.

Experienced Biopharma & Technology Founder, Executive & Board Member with a demonstrated history of working in the Life Sciences & Information Technology industries across continents.